Phase 2 Clinical Trial Results

Our Phase 1 clinical trials evaluated the safety and established the recommended Phase 2 dose of OGX-011 in combination with either docetaxel chemotherapy (two different schedules), gemcitabine/cisplatin chemotherapy or hormone ablation therapy. In all clinical trials, 640 mg was established as the Phase 2 dose.

We have conducted five Phase 2 clinical trials of OGX-011 to further evaluate the safety and efficacy of OGX-011 in combination with various cancer therapies for prostate, non-small cell lung and breast cancer, as further described below.

Prostate Cancer
	Final Results of Phase 2 Clinical Trial in Patients Receiving First-Line Chemotherapy Treatment for Castrate Resistant Prostate Cancer (Study OGX-011-03)
	Phase 2 Clinical Trial - Hormone Ablation Therapy in Patients with Localized Prostate Cancer (Study OGX-011-04)
	Preliminary Results of a Phase 2 Clinical Trial in Patients Receiving Second-Line Chemotherapy for Treatment of Hormone Refractory Prostate Cancer (Study OGX-011-07)
Lung Cancer
	Preliminary Results of Phase 2 Clinical Trial in Patients Treated with First-Line Chemotherapy for Non-Small Cell Lung Cancer (Study OGX-011-05)
Breast Cancer
	Preliminary Results of Phase 2 Clinical Trial in Patients with Advanced Breast Cancer (OGX-011-06)